RedHill Biopharma (RDHL) Corporate presentation summary

Corporate highlights and financials

• Focuses on U.S. commercialization and development of drugs for GI, infectious diseases, and oncology, with $4.1M net revenues and 60.6% gross margin in H1 2025.

• Strengthened U.S. commercial operations through a $4M strategic partnership with Cumberland Pharmaceuticals, including a 30% stake in the Talicia business.

• Cash balance as of June 30, 2025, was $3M, with equity financing capacity of $31.7M as of December 2025.

Commercial product: Talicia

• Talicia is the #1 branded H. pylori therapy among U.S. gastroenterologists, FDA-approved, and launched in the U.S. and UAE.

• Listed as a first-line option in the 2024 ACG Guideline, with >90% eradication rates in adherent populations and minimal resistance to its antibiotic components.

• Broad managed care coverage, with formulary access for over 204 million Americans and preferred status on major commercial and government formularies.

• Supported by two positive Phase 3 studies, demonstrating high efficacy and safety.

• Protected by patents through 2042 and FDA QIDP designation, granting market exclusivity through 2027.

R&D pipeline overview

• RHB-102 (Bekinda): Extended-release ondansetron for GI intolerance, gastroenteritis, IBS-D, and oncology support, with positive Phase 2 and 3 results and a global licensing deal (ex-North America) with Hyloris Pharmaceuticals.

• RHB-204: Fixed-dose antibiotic combination for MAP-positive Crohn's disease and pulmonary NTM, with strong patent protection and planned Phase 2 study.

• Opaganib: Oral SPHK2 inhibitor for oncology, COVID-19, Ebola, and metabolic diseases, with positive Phase 1/2 results and ongoing Phase 2 studies in prostate cancer.

• RHB-107 (upamostat): Oral serine protease inhibitor for COVID-19 and oncology, with positive Phase 2 COVID-19 data and broad antiviral potential.